NEWS
-
05/06/2022
Tempus Announces Agreement With the United States Department of Veterans Affairs National Precision Oncology Program To Expand Access to Genomic Testing for Veterans With Cancer
Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year agreement with the United States Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) designed to expand access to Tempus’ portfolio of next-generation sequencing offerings to support physicians in delivering personalized treatment approaches for their p...
-
04/08/2022
Tempus Announces Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2022
Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which convenes in New Orleans from April 8th until April 13th, 2022. The presented research demonstrates how Tempus’ comprehensive genomic sequencing capabilities generate high-quali...
-
03/21/2022
Tempus’ Edge Platform Leverages Data & AI to Identify Therapeutic Options for Patients Earlier in the Treatment Journey
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide. With access to over 50 petabytes of de-identified multi...
-
02/08/2022
Tempus Announces the Acquisition of Highline Sciences
Tempus, a leader in artificial intelligence and precision medicine, today announced the acquisition of Highline Sciences, a specialized, full-service clinical contract research organization (CRO) focused on oncology. Highline Sciences manages and executes on early and late-stage clinical trials, applying a customized approach to each study. Highline’s capabilities and expertise will he...
-
Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 Mutations
Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and safety of ZEJULA (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor used for patients with advanced or metastatic solid tumors and a germline...
-
12/07/2021
Tempus Announces Six Abstracts Accepted for Poster Presentation at the 2021 San Antonio Breast Cancer Symposium
Tempus, a leader in artificial intelligence and precision medicine, today announced six abstracts accepted for poster sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place December 7 - 10. The presented findings highlight the unique insights that Tempus’ data and smart diagnostics generate to advance breast cancer research. ...
-
12/01/2021
Tempus Announces Agreement with Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the Discovery and Development of Oncology Therapies
Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research & Development, LLC (Janssen). The expanded scope is anchored in new AI-based work, in which Tempus will collaborate with a multidisciplinary team of data scientists at Janssen to enhance the discov...
-
11/19/2021
Tempus Signs Strategic Collaboration Agreement with AstraZeneca to Advance Oncology Therapeutics
Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community. By combining the capa...
-
11/18/2021
Tempus Accelerates its EHR Integration Scope with Epic
Tempus expands its existing provider EHR integrations to offer physicians seamless access to its genomic testing Tempus, a leader in artificial intelligence and precision medicine, announced that it is working with Epic to offer providers in-workflow integrations at scale. Since its founding, Tempus has strived to provide physicians seamles...
-
11/16/2021
Tempus Incorporates OncoKB Data and NCCN Guidelines Into Its Clinical Reports
Tempus is integrating information from the Memorial Sloan Kettering Cancer Center’s OncoKB database and NCCN Guidelines into its clinical reports, providing physicians robust, well-vetted guidelines at their fingertips Tempus, a leader in artificial intelligence and precision medicine, today announced that it will incorporate data from both the Memor...
